Prothena Corp Public (PRTA) Capital Expenditures (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Capital Expenditures of $10000.0 for Q3 2025, up 11.11% year-over-year from $9000.0 in Q3 2024, and down 88.37% quarter-over-quarter from $86000.0 in Q2 2025.
Powered by 
Analysis
Prothena Corp Public (PRTA) Capital Expenditures (2012 - 2026) Analysis & Trends
Prothena Corp Public's Capital Expenditures history runs 14 years deep, the most recent figure standing at $10000.0 for Q3 2025.
- In Q3 2025, Capital Expenditures rose 11.11% year-over-year to $10000.0; the TTM figure through Mar 2026 stood at $96000.0 (down 59.49% YoY), while the FY2025 annual figure was $138000.0, down 53.69% from the prior year.
- Capital Expenditures for Q3 2025 stood at $10000.0, down from $86000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $1.5 million in Q4 2023, with the low at $9000.0 in Q3 2024.
- The 5-year median for Capital Expenditures is $116500.0 (2022), against an average of $238055.6.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures jumped 925.83% in 2023, then plunged 97.96% in 2024.
- Prothena Corp Public's Capital Expenditures stood at $319000.0 in 2021, then plunged by 52.66% to $151000.0 in 2022, then surged by 925.83% to $1.5 million in 2023, then sank by 97.22% to $43000.0 in 2024, then sank by 76.74% to $10000.0 in 2025.
- Business Quant data shows PRTA's Capital Expenditures at $10000.0 in Q3 2025, $86000.0 in Q2 2025, and $42000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Prothena Corp Public | 506.33 Mn | 218.13 Mn | - | 652,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 652,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 86,000.00 |
| Mar 31, 2025 | 42,000.00 |
| Dec 31, 2024 | 43,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 143,000.00 |
| Mar 31, 2024 | 103,000.00 |
| Dec 31, 2023 | 1.55 Mn |
| Sep 30, 2023 | 442,000.00 |
| Jun 30, 2023 | 771,000.00 |
| Mar 31, 2023 | 48,000.00 |
| Dec 31, 2022 | 151,000.00 |
| Sep 30, 2022 | 130,000.00 |
| Jun 30, 2022 | 161,000.00 |
| Mar 31, 2022 | 22,000.00 |
| Dec 31, 2021 | 319,000.00 |
| Sep 30, 2021 | 208,000.00 |
| Mar 31, 2021 | 48,000.00 |
| Dec 31, 2020 | 51,000.00 |